Purdue Pharma LP

Purdue Pharma LP logo
🇺🇸United States
Ownership
Private
Established
1892-01-01
Employees
5K
Market Cap
-
Website
http://www.purduepharma.com

Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015

First Posted Date
2010-05-19
Last Posted Date
2012-09-03
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
354
Registration Number
NCT01125917
Locations
🇺🇸

Palm Beach Research Center, West Palm Beach, Florida, United States

🇺🇸

Pharmquest, Greensboro, North Carolina, United States

🇺🇸

Wake Research Associates, LLC, Raleigh, North Carolina, United States

and more 78 locations

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

First Posted Date
2010-04-09
Last Posted Date
2010-05-25
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
84
Registration Number
NCT01101191
Locations
🇺🇸

Covance Clinical Research Unit Honolulu, Honolulu, Hawaii, United States

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

First Posted Date
2010-04-09
Last Posted Date
2015-11-18
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
58
Registration Number
NCT01101321
Locations
🇺🇸

Covance Clinical Research Unit Honolulu, Honolulu, Hawaii, United States

To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

First Posted Date
2010-04-09
Last Posted Date
2011-10-10
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
79
Registration Number
NCT01101178
Locations
🇺🇸

Covance Clinical Research Unit Madison, Madison, Wisconsin, United States

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets Manufactured at Two Different Facilities

First Posted Date
2010-04-09
Last Posted Date
2010-05-25
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
55
Registration Number
NCT01101308
Locations
🇺🇸

Covance Clinical Research Unit Madison, Madison, Wisconsin, United States

To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

First Posted Date
2010-04-09
Last Posted Date
2010-05-11
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
92
Registration Number
NCT01101165
Locations
🇺🇸

Covance Clinical Research Unit - Evansville, Evansville, Indiana, United States

A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

First Posted Date
2010-04-08
Last Posted Date
2010-05-25
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
84
Registration Number
NCT01100086
Locations
🇺🇸

Covance Clinical Research Unit Madison, Madison, Wisconsin, United States

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

First Posted Date
2010-04-08
Last Posted Date
2010-05-11
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
88
Registration Number
NCT01100320
Locations
🇺🇸

Covance Clinical Research Unit - Austin, Austin, Texas, United States

A Study to Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

First Posted Date
2010-04-07
Last Posted Date
2010-05-06
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
85
Registration Number
NCT01099709
Locations
🇺🇸

Covance Clinical Research Unit, Honolulu, Hawaii, United States

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

First Posted Date
2007-09-18
Last Posted Date
2012-09-10
Lead Sponsor
Purdue Pharma LP
Target Recruit Count
567
Registration Number
NCT00531427
Locations
🇺🇸

Stat-Lab I, Inc., Baton Rouge, Louisiana, United States

🇺🇸

Arthritis Clinic, PLLC, Jackson, Tennessee, United States

🇺🇸

Coastal Pain Management, Bradenton, Florida, United States

and more 23 locations
© Copyright 2024. All Rights Reserved by MedPath